Research programme: autoimmune disorder therapeutics - Gliknik

Drug Profile

Research programme: autoimmune disorder therapeutics - Gliknik

Alternative Names: GL-2045

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gliknik
  • Class Biobetters; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 03 Apr 2018 Gliknik and University of Maryland has patent protection for use of recombinant compounds with at least two human IgG1 Fc domains in USA
  • 10 Aug 2015 GL 2045 receives Orphan Drug status for Chronic inflammatory demyelinating polyradiculoneuropathy in USA
  • 30 Sep 2013 GL-2045 licensed to Pfizer worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top